A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients
ConditionChronic Spontaneous Urticaria
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-100
SponsorNovartis Pharmaceuticals
About this trial
This is a United States (US) based, prospective, non-interventional, provider-referral study to evaluate the real-world effectiveness and patient-centered outcomes of remibrutinib in chronic spontaneous urticaria (CSU) patients using validated patient reported outcome (PRO) tools.
Eligibility criteria
Qualifiers
Have an active medical license and be board certified/board eligible allergist or dermatologist in the US. Nurse practitioners and physician assistant practicing in allergy and dermatology are eligible.
Manage CSU patients within their practice.
Enrolled in the research network or are referred HCPs who agree to participate.
Have the requisite patient population based on study inclusion/
Disqualifiers
≥ 18 years of age.
Diagnosed with CSU by an HCP.
Have received a prescription for remibrutinib or dupilumab and are expected to initiate treatment.
Have access to an electronic device with internet capabilities.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
350 Participants
are grouped into 2 trial groupsSponsors and collaborators
Source ClinicalTrials.gov